...
首页> 外文期刊>Journal of child neurology >Neurodevelopmental Treatment (Bobath) for Children With Cerebral Palsy: A Systematic Review
【24h】

Neurodevelopmental Treatment (Bobath) for Children With Cerebral Palsy: A Systematic Review

机译:脑瘫儿童的神经发育治疗(Bobath):系统审查

获取原文
获取原文并翻译 | 示例
           

摘要

Aim: To assess the effects of neurodevelopmental treatment for children with cerebral palsy. Methods: We conducted a systematic review following the recommendations of the Cochrane Handbook for Systematic Reviews of Interventions and reported in accordance to PRISMA Statement. Through a comprehensive literature search we considered all randomized clinical trials that compared neurodevelopmental treatment with conventional physical therapy for children with cerebral palsy. We used the Cochrane Risk of Bias Table to assess the risk of bias of the included randomized clinical trial, and the GRADE approach to evaluate the certainty of the body of the evidence. Results: We found 3 randomized clinical trials (2 published and 1 ongoing) comprising 66 children. Published randomized clinical trials presented methodological and reporting limitations and only 1 provided data for outcomes of interest. No difference between neurodevelopmental treatment and conventional physical therapy was found for gross motor function (mean difference 1.40; 95% confidence interval –5.47 to 8.27, low certainty evidence). Conclusion: This review found that the effects of neurodevelopmental treatment for children with cerebral palsy are still uncertain. Further studies are required to assess the efficacy and safety of neurodevelopmental treatment for this purpose and until there, current evidence do not support its routinely use in practice. Number of protocol registration in PROSPERO database: CRD42017082817 (available from https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=82817 ).
机译:目的:评估脑瘫儿童神经发育治疗的影响。方法:在Cochrane手册的建议下进行系统审查,用于系统性审查的干预措施,并按照PRISMA声明报告。通过全面的文学搜索,我们认为所有随机临床试验,将神经发育治疗与脑瘫患儿的常规物理治疗进行了比较。我们利用偏见表的Cochrane风险来评估包括随机临床试验的偏差的风险,以及评估证据体内确定性的等级方法。结果:我们发现3名随机临床试验(2名发布,1个持续),包括66名儿童。出版的随机临床试验提出了方法论和报告限制,只有1个提供了利益结果的数据。没有发现神经开发治疗和常规物理治疗的差异用于总电机功能(平均差异1.40; 95%置信区间-5.47至8.27,确定性证据)。结论:本综述发现,脑瘫患儿神经发育治疗的影响仍然不确定。进一步的研究是为了评估神经发育治疗的疗效和安全性为此目的,直到那时,目前的证据不支持其在实践中的定期使用。 Prospero数据库中的协议登记次数:CRD42017082817(可从https://www.crd.york.ac.uk/prospero/display_record.php?recordid=82817)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号